

Josã© P S Henriques

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6687688/publications.pdf>

Version: 2024-02-01

252
papers

13,760
citations

20817

60
h-index

24258

110
g-index

264
all docs

264
docs citations

264
times ranked

9907
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention. <i>Circulation</i> , 2012, 126, 1717-1727.	1.6	680
2	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 278-287.	2.8	612
3	A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. <i>European Heart Journal</i> , 2008, 30, 459-468.	2.2	452
4	Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2016, 42, 1922-1934.	8.2	405
5	Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. <i>New England Journal of Medicine</i> , 2019, 380, 1397-1407.	27.0	373
6	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. <i>New England Journal of Medicine</i> , 2017, 376, 2319-2328.	27.0	363
7	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. <i>Circulation</i> , 2019, 139, 1249-1258.	1.6	353
8	Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade. <i>Circulation</i> , 2003, 107, 2115-2119.	1.6	350
9	Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate Severity. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 301-311.	3.9	322
10	Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1622-1632.	2.8	300
11	A Prospective Feasibility Trial Investigating the Use of the Impella 2.5 System in Patients Undergoing High-Risk Percutaneous Coronary Intervention (The PROTECT I Trial). <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 91-96.	2.9	295
12	Plaque Instability Frequently Occurs Days or Weeks Before Occlusive Coronary Thrombosis. <i>Circulation</i> , 2005, 111, 1160-1165.	1.6	287
13	Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2017, 38, 3523-3531.	2.2	280
14	Percutaneous Left-Ventricular Support With the Impella-2.5 Assist Device in Acute Cardiogenic Shock. <i>Circulation: Heart Failure</i> , 2013, 6, 23-30.	3.9	278
15	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 420-433.	1.6	263
16	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 952-961.	2.9	260
17	Supported High-Risk Percutaneous Coronary Intervention With the Impella 2.5 Device. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2430-2434.	2.8	210
18	Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1128-1134.	2.9	208

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. <i>European Heart Journal</i> , 2012, 33, 768-775.	2.2	206
20	Safety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5. <i>American Journal of Cardiology</i> , 2006, 97, 990-992.	1.6	205
21	Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 532-537.	1.7	161
22	Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. <i>International Journal of Cardiology</i> , 2015, 201, 684-691.	1.7	160
23	Stent Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1081-1092.	2.9	159
24	A single dose of erythropoietin in ST-elevation myocardial infarction. <i>European Heart Journal</i> , 2010, 31, 2593-2600.	2.2	144
25	Presence of Older Thrombus Is an Independent Predictor of Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Thrombus Aspiration During Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2008, 118, 1810-1816.	1.6	135
26	Left ventricular unloading during veno-arterial ECMO: a review of percutaneous and surgical unloading interventions. <i>Perfusion (United Kingdom)</i> , 2019, 34, 98-105.	1.0	130
27	Impact of Multivessel Coronary Disease on Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Is Due to the Presence of a Chronic Total Occlusion. <i>American Journal of Cardiology</i> , 2006, 98, 1165-1169.	1.6	126
28	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. <i>International Journal of Cardiology</i> , 2015, 187, 90-96.	1.7	126
29	Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. <i>American Heart Journal</i> , 2004, 148, 399-404.	2.7	124
30	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	2.2	121
31	Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. <i>EuroIntervention</i> , 2015, 10, 1160-1168.	3.2	118
32	Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). <i>American Journal of Cardiology</i> , 2014, 113, 222-228.	1.6	116
33	Left Ventricular Unloading During Veno-Arterial ECMO: A Simulation Study. <i>ASAIO Journal</i> , 2019, 65, 11-20.	1.6	112
34	Global Chronic Total Occlusion Crossing Algorithm. <i>Journal of the American College of Cardiology</i> , 2021, 78, 840-853.	2.8	111
35	Chronic Total Occlusions in Sweden – A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). <i>PLoS ONE</i> , 2014, 9, e103850.	2.5	108
36	Genousâ„¢ endothelial progenitor cell capturing stent vs. the Taxus LibertÃ© stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. <i>European Heart Journal</i> , 2010, 31, 1055-1064.	2.2	106

#	ARTICLE	IF	CITATIONS
37	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. <i>Intensive Care Medicine</i> , 2018, 44, 847-856.	8.2	106
38	Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2010, 105, 955-959.	1.6	105
39	Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment. <i>Heart</i> , 2014, 100, 951-959.	2.9	102
40	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1097-1105.	2.9	101
41	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2017, 69, 358-360.	2.8	98
42	Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2006, 27, 2499-2510.	2.2	97
43	The ICM research agenda on extracorporeal life support. <i>Intensive Care Medicine</i> , 2017, 43, 1306-1318.	8.2	94
44	The Prognostic Value of Bleeding Academic Research Consortium (BARC)-Defined Bleeding Complications in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1866-1875.	2.8	93
45	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	2.8	93
46	Effects of mechanical left ventricular unloading by impella on left ventricular dynamics in high-risk and primary percutaneous coronary intervention patients. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 187-194.	1.7	91
47	Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 29-36.	2.8	91
48	The impact of multivessel disease with and without a coexisting chronic total occlusion on short- and long-term mortality in ST-segment elevation myocardial infarction patients with and without cardiogenic shock. <i>European Journal of Heart Failure</i> , 2013, 15, 425-432.	7.1	90
49	Left Ventricular Unloading in Acute ST-Segment Elevation Myocardial Infarction Patients Is Safe and Feasible and Provides Acute and Sustained Left Ventricular Recovery. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1044-1046.	2.8	89
50	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 275-283.	2.9	88
51	Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 133-143.	2.9	83
52	Impact of Coronary Microvascular Function on Long-term Cardiac Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 207-215.	3.9	77
53	Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. <i>International Journal of Cardiology</i> , 2016, 202, 894-896.	1.7	76
54	Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 164-172.	1.0	72

#	ARTICLE	IF	CITATIONS
55	Interferon- γ Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice. <i>Circulation Research</i> , 2008, 102, 1286-1294.	4.5	66
56	Impaired Coronary Autoregulation Is Associated With Long-term Fatal Events in Patients With Stable Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 329-335.	3.9	65
57	Prognostic Impact of Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1535-1544.	2.9	65
58	Coronary Angiography After Cardiac Arrest Without ST Segment Elevation. <i>JAMA Cardiology</i> , 2020, 5, 1358.	6.1	65
59	Improved microcirculation in patients with an acute ST-elevation myocardial infarction treated with the Impella LP2.5 percutaneous left ventricular assist device. <i>Clinical Research in Cardiology</i> , 2009, 98, 311-318.	3.3	63
60	Percutaneous cardiac support devices for cardiogenic shock: current indications and recommendations. <i>Heart</i> , 2012, 98, 1246-1254.	2.9	62
61	Head-to-head comparison of basal stenosis resistance index, instantaneous wave-free ratio, and fractional flow reserve: diagnostic accuracy for stenosis-specific myocardial ischaemia. <i>EuroIntervention</i> , 2015, 11, 914-925.	3.2	62
62	Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. <i>Heart</i> , 2010, 96, 843-847.	2.9	60
63	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. <i>Trials</i> , 2010, 11, 89.	1.6	58
64	Clinical and Procedural Characteristics Associated With Higher Radiation Exposure During Percutaneous Coronary Interventions and Coronary Angiography. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 501-506.	3.9	58
65	Right ventricular dysfunction is an independent predictor for mortality in ST-elevation myocardial infarction patients presenting with cardiogenic shock on admission. <i>European Journal of Heart Failure</i> , 2010, 12, 276-282.	7.1	57
66	Anxiety levels of patients undergoing coronary procedures in the catheterization laboratory. <i>International Journal of Cardiology</i> , 2017, 228, 926-930.	1.7	55
67	Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. <i>Heart</i> , 2018, 104, 1432-1438.	2.9	55
68	Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 338-349.	1.0	55
69	Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. <i>Heart</i> , 2010, 96, 1968-1972.	2.9	52
70	CTCA for detection of significant coronary artery disease in routine TAVI work-up. <i>Netherlands Heart Journal</i> , 2018, 26, 591-599.	0.8	50
71	Histopathological Features of Aspirated Thrombi after Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2009, 4, e5817.	2.5	49
72	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 37, 155-164.	2.1	49

#	ARTICLE	IF	CITATIONS
73	A Systematic Review and Meta-Analysis on Primary Percutaneous Coronary Intervention of an Unprotected Left Main Coronary Artery Culprit Lesion in the Setting of Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 317-324.	2.9	48
74	Efficacy of the RADPAD Protection Drape in Reducing Operators'™ Radiation Exposure in the Catheterization Laboratory. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	48
75	Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 76-82.	1.7	46
76	Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. <i>European Heart Journal</i> , 2012, 33, 1076-1084.	2.2	44
77	Culprit Vessel-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment-Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	44
78	In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. <i>American Heart Journal</i> , 2007, 154, 1184-1190.	2.7	43
79	Radiation Exposure During Percutaneous Coronary Interventions and Coronary Angiograms Performed by the Radial Compared With the Femoral Route. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 752-757.	2.9	41
80	Amsterdam Investigator-initiated Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design. <i>American Heart Journal</i> , 2014, 167, 133-140.	2.7	41
81	Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 19, 53.	3.3	41
82	Incidence, Predictors, and Impact of Vascular Complications After Transfemoral Transcatheter Aortic Valve Implantation With the SAPIEN 3 Prosthesis. <i>American Journal of Cardiology</i> , 2018, 121, 1231-1238.	1.6	41
83	Comparison of Long-Term Mortality After Percutaneous Coronary Intervention in Patients Treated for Acute ST-Elevation Myocardial Infarction Versus Those With Unstable and Stable Angina Pectoris. <i>American Journal of Cardiology</i> , 2009, 104, 333-337.	1.6	40
84	Prognostic Value of Admission Hemoglobin Levels in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2007, 99, 1201-1202.	1.6	38
85	Two-year follow-up of the genous, endothelial progenitor cell capturing stent versus the taxus libert stent in patients with De Novo coronary artery lesions with a high risk of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 189-195.	1.7	38
86	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2018, 13, 1565-1573.	3.2	35
87	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 622-630.	2.9	34
88	Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. <i>American Heart Journal</i> , 2014, 167, 472-479.e5.	2.7	34
89	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. <i>Nature Reviews Cardiology</i> , 2022, 19, 195-208.	13.7	34
90	Contemporary overview and clinical perspectives of chronic total occlusions. <i>Nature Reviews Cardiology</i> , 2014, 11, 458-469.	13.7	33

#	ARTICLE	IF	CITATIONS
91	Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users. <i>Netherlands Heart Journal</i> , 2015, 23, 161-165.	0.8	30
92	Impact of Collateral Circulation on Survival in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With a Concomitant Chronic Total Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 906-914.	2.9	30
93	Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1009-1015.	1.0	30
94	Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 2035-2040.	1.6	29
95	The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective. <i>Journal of Medical Economics</i> , 2013, 16, 381-390.	2.1	28
96	Timing of Mortality After Severe Bleeding and Recurrent Myocardial Infarction in Patients With ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2013, 6, 391-398.	3.9	28
97	Coronary angiography after cardiac arrest: Rationale and design of the COACT trial. <i>American Heart Journal</i> , 2016, 180, 39-45.	2.7	28
98	Lactate is a Prognostic Factor in Patients Admitted With Suspected ST-Elevation Myocardial Infarction. <i>Shock</i> , 2019, 51, 321-327.	2.1	28
99	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 1038-1046.	2.2	28
100	Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. <i>EuroIntervention</i> , 2013, 9, 195-203.	3.2	27
101	Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. <i>EuroIntervention</i> , 2018, 14, e426-e433.	3.2	26
102	Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. <i>EuroIntervention</i> , 2014, 10, 90-96.	3.2	26
103	Long-term safety and sustained left ventricular recovery: long-term results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2011, 6, 860-865.	3.2	26
104	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2014, 113, 229-235.	1.6	25
105	Prognostic implications of microcirculatory perfusion versus macrocirculatory perfusion in cardiogenic shock: a CULPRIT-SHOCK substudy. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 108-119.	1.0	25
106	Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. <i>Journal of Invasive Cardiology</i> , 2012, 24, 484-8.	0.4	25
107	Percutaneous mechanical cardiac assist in myocardial infarction. Where are we now, where are we going?. <i>Acute Cardiac Care</i> , 2007, 9, 222-230.	0.2	24
108	Role of fractional and coronary flow reserve in clinical decision making in intermediate coronary lesions. <i>Interventional Cardiology</i> , 2009, 1, 237-255.	0.0	24

#	ARTICLE	IF	CITATIONS
109	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?. Netherlands Heart Journal, 2010, 18, 451-453.	0.8	24
110	Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission.. Acute Cardiac Care, 2010, 12, 51-57.	0.2	24
111	Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 Years). Catheterization and Cardiovascular Interventions, 2013, 82, 85-92.	1.7	24
112	Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention, 2013, 9, 841-853.	3.2	24
113	Increased hyperaemic coronary microvascular resistance adds to the presence of myocardial ischaemia. EuroIntervention, 2014, 9, 1423-1431.	3.2	23
114	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute ST-segment elevation myocardial infarction: Results of the HORIZONS-AMI trial. Catheterization and Cardiovascular Interventions, 2015, 85, 335-342.	1.7	22
115	Guideline-defined futility or patient-reported outcomes to assess treatment success after TAVI: what to use? Results from a prospective cohort study with long-term follow-up. Open Heart, 2018, 5, e000879.	2.3	21
116	Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2051.	2.4	21
117	Time to Return of Spontaneous Circulation and Survival: When to Transport in out-of-Hospital Cardiac Arrest?. Prehospital Emergency Care, 2021, 25, 171-181.	1.8	21
118	CT determined psoas muscle area predicts mortality in women undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2019, 93, E248-E254.	1.7	20
119	Comparison of Outcomes of Transfemoral Aortic Valve Implantation in Patients >90 With Those <90 Years of Age. American Journal of Cardiology, 2018, 121, 1581-1586.	1.6	18
120	Adjunctive thrombus aspiration versus conventional percutaneous coronary intervention in ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 81, 922-929.	1.7	16
121	Predictors and prognostic consequence of gastrointestinal bleeding in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2015, 184, 128-134.	1.7	15
122	The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the) Interventions, 2016, 9, .	3.9	15
123	Basal stenosis resistance index derived from simultaneous pressure and flow velocity measurements. EuroIntervention, 2016, 12, e199-e207.	3.2	15
124	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2012, 34, 165-179.	2.1	14
125	Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent. Heart, 2014, 100, 479-486.	2.9	14
126	Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock. PLoS ONE, 2020, 15, e0235762.	2.5	14

#	ARTICLE	IF	CITATIONS
127	Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial. <i>EuroIntervention</i> , 2018, 14, e434-e442.	3.2	14
128	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. <i>Journal of Clinical Medicine</i> , 2022, 11, 1361.	2.4	14
129	First report of the use of longâ€tapered sirolimusâ€eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E299-E307.	1.7	13
130	Procedural Outcome and Midterm Survival of Lower Risk Transfemoral Transcatheter Aortic Valve Implantation Patients Treated With the SAPIEN XT or SAPIEN 3 Device. <i>American Journal of Cardiology</i> , 2018, 121, 856-861.	1.6	13
131	Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Longâ€Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverterâ€Defibrillator (the eCTOPyâ€inâ€CD Study). <i>Journal of the American Heart Association</i> , 2018, 7,	3.7	13
132	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. <i>European Radiology</i> , 2020, 30, 600-608.	4.5	13
133	Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography. <i>EuroIntervention</i> , 2015, 11, 877-884.	3.2	13
134	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. <i>Cardiovascular Drugs and Therapy</i> , 2013, 27, 433-439.	2.6	12
135	Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: Aâ€weighted meta-analysis of seven randomised controlled trials including 5577 patients. <i>Netherlands Heart Journal</i> , 2017, 25, 429-438.	0.8	12
136	Aortic valve calcification volumes and chronic brain infarctions in patients undergoing transcatheter aortic valve implantation. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 2123-2133.	1.5	12
137	Gender differences in quality of life in coronary artery disease patients with comorbidities undergoing coronary revascularization. <i>PLoS ONE</i> , 2020, 15, e0234543.	2.5	12
138	New percutaneous mechanical left ventricular support for acute MI: the AMC MACH program. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 62-63.	3.3	11
139	Current status of the Xience V^{â€}everolimus-eluting coronary stent system. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1363-1374.	1.5	11
140	Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI. <i>Thrombosis and Haemostasis</i> , 2013, 109, 961-970.	3.4	11
141	Older coronary thrombus is an independent predictor of 1â€year mortality in acute myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2016, 46, 501-510.	3.4	11
142	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. <i>Open Heart</i> , 2018, 5, e000810.	2.3	11
143	3-Year Clinical Outcomes of the PRISON-IV Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1747-1749.	2.9	11
144	The dynamics in health-related quality of life of patients with stable coronary artery disease were revealed: a network analysis. <i>Journal of Clinical Epidemiology</i> , 2019, 107, 116-123.	5.0	11

#	ARTICLE	IF	CITATIONS
145	External validation of existing prediction models of 30-day mortality after Transcatheter Aortic Valve Implantation (TAVI) in the Netherlands Heart Registration. <i>International Journal of Cardiology</i> , 2020, 317, 25-32.	1.7	11
146	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial. <i>EuroIntervention</i> , 2019, 15, 603-606.	3.2	11
147	Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. <i>EuroIntervention</i> , 2016, 12, e557-e565.	3.2	11
148	Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. <i>Acute Cardiac Care</i> , 2009, 11, 107-112.	0.2	10
149	A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study. <i>Trials</i> , 2012, 13, 240.	1.6	10
150	Predicting hospitalisation duration after transcatheter aortic valve implantation. <i>Open Heart</i> , 2017, 4, e000549.	2.3	10
151	Electrocardiographic changes after successful recanalization of a chronic total coronary occlusion. A systematic review and meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 221-228.	0.8	10
152	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. <i>Structural Heart</i> , 2018, 2, 53-57.	0.6	10
153	Quantification of Myocardial Mass Subtended by a Coronary Stenosis Using Intracoronary Physiology. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007322.	3.9	10
154	Influence of response shift and disposition on patient-reported outcomes may lead to suboptimal medical decisions: a medical ethics perspective. <i>BMC Medical Ethics</i> , 2019, 20, 61.	2.4	10
155	Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a systematic review and meta-analysis of randomised trials. <i>Netherlands Heart Journal</i> , 2021, 29, 30-41.	0.8	10
156	Impella CP Implantation during Cardiopulmonary Resuscitation for Cardiac Arrest: A Multicenter Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 339.	2.4	10
157	Impella versus extracorporeal life support in cardiogenic shock: a propensity score adjusted analysis. <i>ESC Heart Failure</i> , 2021, 8, 953-961.	3.1	10
158	DEtection of ProxImal Coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration). <i>European Radiology</i> , 2022, 32, 143-151.	4.5	10
159	Identification and treatment of the vulnerable coronary plaque. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 1.	1.4	10
160	External validation of the GRACE risk score and the riskâ€“treatment paradox in patients with acute coronary syndrome. <i>Open Heart</i> , 2022, 9, e001984.	2.3	10
161	Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. <i>EuroIntervention</i> , 2022, 17, 1340-1347.	3.2	10
162	Sensor-Augmented Insulin Pump Therapy to Treat Hyperglycemia at the Coronary Care Unit: A Randomized Clinical Pilot Trial. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 537-542.	4.4	9

#	ARTICLE	IF	CITATIONS
163	Short- and Long-Term Prognostic Value of the TIMI Risk Score after Primary Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2013, 26, 8-13.	1.2	9
164	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention " From the PROTECT II randomized trial. <i>International Journal of Cardiology</i> , 2015, 189, 272-278.	1.7	9
165	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 441-451.	2.1	9
166	Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial. <i>Journal of Interventional Cardiology</i> , 2018, 31, 580-587.	1.2	9
167	Clinical Implications of Distal Vessel Stenosis After Successful Coronary Chronic Total Occlusion Recanalization. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2343-2345.	2.9	9
168	The effect of immediate coronary angiography after cardiac arrest without ST-segment elevation on left ventricular function. A sub-study of the COACT randomised trial. <i>Resuscitation</i> , 2021, 164, 93-100.	3.0	9
169	Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. <i>EuroIntervention</i> , 2015, 10, 1272-1275.	3.2	9
170	First report on long-term clinical results after treatment of coronary bifurcation lesions with the Tryton dedicated bifurcation stent. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 759-765.	1.7	8
171	Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. <i>Netherlands Heart Journal</i> , 2015, 23, 477-482.	0.8	8
172	A SMILE and a Frown. <i>Journal of the American College of Cardiology</i> , 2016, 67, 273-274.	2.8	8
173	Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2018, 122, 1661-1669.	1.6	8
174	Online Quantitative Aortographic Assessment of Aortic Regurgitation After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 531-538.	2.9	8
175	Response shift after coronary revascularization. <i>Quality of Life Research</i> , 2022, 31, 437-450.	3.1	8
176	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. <i>EuroIntervention</i> , 2016, 12, 423-430.	3.2	8
177	Deep learning-based whole-heart segmentation in 4D contrast-enhanced cardiac CT. <i>Computers in Biology and Medicine</i> , 2022, 142, 105191.	7.0	8
178	Evaluation of a Fully Automatic Deep Learning-Based Method for the Measurement of Psoas Muscle Area. <i>Frontiers in Nutrition</i> , 2022, 9, .	3.7	8
179	Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 827-831.	1.5	7
180	Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Does Coronary Pressure Never Lie?. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014, 16, 294.	0.9	7

#	ARTICLE	IF	CITATIONS
181	Predictors of medium-term mortality in patients hospitalised with coronary artery disease in a resource-limited South-East Asian setting. <i>Open Heart</i> , 2018, 5, e000801.	2.3	7
182	Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention. <i>Open Heart</i> , 2018, 5, e000833.	2.3	7
183	Tele-ECG consulting and outcomes on primary care patients in a low-to-middle income population: the first experience from Makassar telemedicine program, Indonesia. <i>BMC Family Practice</i> , 2020, 21, 247.	2.9	7
184	Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1171-1182.	2.6	7
185	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 200-208.	2.1	6
186	Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication. <i>European Heart Journal</i> , 2016, 37, 1104-1112.	2.2	6
187	Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E106-E114.	1.7	6
188	The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial. <i>Journal of Electrocardiology</i> , 2018, 51, 906-912.	0.9	6
189	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1189-1198.	1.5	6
190	Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion(from the EXPLORE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1035-1043.	1.6	6
191	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice. <i>Journal of Clinical Medicine</i> , 2020, 9, 3173.	2.4	6
192	Collagenase to facilitate guidewire crossing in chronic total occlusion PCI – The Total Occlusion Study in Coronary Arteries (TOSCA) trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1065-1073.	1.7	6
193	Monocytic microRNA profile associated with coronary collateral artery function in chronic total occlusion patients. <i>Scientific Reports</i> , 2017, 7, 1532.	3.3	5
194	Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2347-2348.	2.8	5
195	Revascularization Strategies in Cardiogenic Shock Patients With MVD. <i>Journal of the American College of Cardiology</i> , 2018, 71, 857-859.	2.8	5
196	Sex differences in patients with out-of-hospital cardiac arrest without ST-segment elevation: A COACT trial substudy. <i>Resuscitation</i> , 2021, 158, 14-22.	3.0	5
197	Outcome and Predictors for Mortality in Patients with Cardiogenic Shock: A Dutch Nationwide Registry-Based Study of 75,407 Patients with Acute Coronary Syndrome Treated by PCI. <i>Journal of Clinical Medicine</i> , 2021, 10, 2047.	2.4	5
198	Ecological momentary assessment versus retrospective assessment for measuring change in health-related quality of life following cardiac intervention. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 98.	1.9	5

#	ARTICLE	IF	CITATIONS
199	Long-term follow-up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 1026-1036.	1.7	4
200	Percutaneous left ventricular assist devices for high-risk percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1247-1255.	1.5	4
201	The first generation ABSORB BVS scaffold; to be or not to be?. <i>Netherlands Heart Journal</i> , 2017, 25, 416-418.	0.8	4
202	Five-year follow-up of the endothelial progenitor cell capturing stent versus the paclitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1212-1218.	1.7	4
203	Cardiology fellows-in-training are exposed to relatively high levels of radiation in the cath lab compared with staff interventional cardiologists' insights from the RECAP trial. <i>Netherlands Heart Journal</i> , 2019, 27, 330-333.	0.8	4
204	Adherence to guideline recommendations for coronary angiography in a poor South-East Asian setting: Impact on short- and medium-term clinical outcomes. <i>Scientific Reports</i> , 2019, 9, 19163.	3.3	4
205	Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 216-221.	1.7	4
206	Angiographic and clinical outcomes of antegrade versus retrograde techniques for chronic total occlusion revascularizations: Insights from the PRISON IV trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E81-E89.	1.7	4
207	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease: AIDA trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 89-96.	1.7	4
208	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. <i>International Journal of Cardiology</i> , 2020, 300, 93-98.	1.7	4
209	Update and, internal and temporal-validation of the FRANCE-2 and ACC-TAVI early-mortality prediction models for Transcatheter aortic Valve Implantation (TAVI) using data from the Netherlands heart registration (NHR). <i>IJC Heart and Vasculature</i> , 2021, 32, 100716.	1.1	4
210	Demonstrating LV unloading on echocardiography during high risk PCI with a left ventricular assist device. <i>Acute Cardiac Care</i> , 2007, 9, 125-126.	0.2	3
211	Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 26-33.	1.7	3
212	Assessment of Cardiac Device Position on Supine Chest Radiograph in the ICU. <i>Critical Care Medicine</i> , 2016, 44, e957-e963.	0.9	3
213	Characteristics and the average 30-day and 6-month clinical outcomes of patients hospitalised with coronary artery disease in a poor South-East Asian setting: the first cohort from Makassar Cardiac Center, Indonesia. <i>BMJ Open</i> , 2018, 8, e021996.	1.9	3
214	Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLORE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 536-545.	1.7	3
215	Brachial Artery Access as a Novel Alternative for Impella 2.5 Insertion. <i>JACC: Case Reports</i> , 2020, 2, 1884-1887.	0.6	3
216	Acute myocardial infarction, chronic total occlusion, and cardiogenic shock: the ultimate triple threat. <i>EuroIntervention</i> , 2018, 14, e252-e254.	3.2	3

#	ARTICLE	IF	CITATIONS
217	Percutaneous assist devices vs. intra-aortic balloon pump for cardiogenic shock: evidence under construction vs. expert opinion. <i>European Heart Journal</i> , 2010, 31, 502-502.	2.2	2
218	Continuous postoperative pericardial flushing method versus standard care for wound drainage after adult cardiac surgery: A randomized controlled trial. <i>EBioMedicine</i> , 2020, 55, 102744.	6.1	2
219	Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusionâ€”A subanalysis of the EXPLORE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1176-1183.	1.7	2
220	Periprocedural Antibiotic Prophylaxis for Transfemoral Transcatheter Aortic Valve Replacement: A Nationwide Survey in the Netherlands. <i>Structural Heart</i> , 2021, 5, 328-329.	0.6	2
221	Admission Lipoprotein-Associated Phospholipase A2 Activity Is Not Associated with Long-Term Clinical Outcomes after ST-Segment Elevation Myocardial Infarction. <i>PLoS ONE</i> , 2014, 9, e96251.	2.5	2
222	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. <i>Interventional Cardiology Review</i> , 2015, 10, 39.	1.6	2
223	Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial. <i>EuroIntervention</i> , 2020, 16, e904-e912.	3.2	2
224	Ischaemic electrocardiogram patterns and its association with survival in out-of-hospital cardiac arrest patients without ST-segment elevation myocardial infarction: a COACT trialsâ€™ post-hoc subgroup analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 535-543.	1.0	2
225	Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1100-E1102.	1.4	1
226	1-Year Clinical Performance of COMBO Stent Versus Xienceâ€™Stent in All-Comers Patients With Coronary Arteryâ€™Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 102-103.	2.9	1
227	Patient delay in women with STEMI: Time to raise awareness. <i>International Journal of Cardiology</i> , 2018, 262, 30-31.	1.7	1
228	Reconstructing Disruptive Life Events Using the RE-LIFE Questionnaire: Further Validation of the â€™Narrative Meaning Making of Life Eventsâ€™ Model Using Multiple Mediation Analysis. <i>Journal of Empirical Theology</i> , 2019, 32, 251-280.	0.8	1
229	Threeâ€™year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimusâ€™eluting stent in routine PCI in patients with diabetes mellitusâ€™ AIDA subâ€™study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 713-720.	1.7	1
230	Continuous postoperative pericardial flushing reduces postoperative bleeding after coronary artery bypass grafting: A randomized trial. <i>EClinicalMedicine</i> , 2021, 31, 100661.	7.1	1
231	Cangrelor Use in Routine Practice: A Two-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2829.	2.4	1
232	Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 631-641.	1.5	1
233	XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: â€™The New Normalâ€™?. <i>Heart International</i> , 2021, 15, 65.	1.4	1
234	Percutaneous Mechanical Support. <i>Interventional Cardiology Clinics</i> , 2013, 2, ix.	0.4	0

#	ARTICLE	IF	CITATIONS
235	Vasoactive and Antiarrhythmic Drugs During Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2013, 2, 665-670.	0.4	0
236	Additional side branch stent placement in patients with long side branch lesions treated with the Tryton dedicated bifurcation side branch stent. <i>International Journal of Cardiology</i> , 2013, 168, 3059-3062.	1.7	0
237	Intracoronary Abciximab in DiabeticÂSTEMIÂPatients. <i>Journal of the American College of Cardiology</i> , 2016, 68, 739-741.	2.8	0
238	Reply. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1758-1759.	2.8	0
239	The first-generation ABSORB BVS: awaiting dissolving outcomes. <i>Netherlands Heart Journal</i> , 2017, 25, 650-652.	0.8	0
240	Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 511-512.	2.9	0
241	Reply. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 506-507.	2.9	0
242	Recurrent myocardial infarction in an aneurysmal coronary artery managed with stent grafts. <i>Coronary Artery Disease</i> , 2018, 29, 171-173.	0.7	0
243	Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report. <i>Journal of Radiology Case Reports</i> , 2019, 13, 9-14.	0.4	0
244	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 565-575.	1.5	0
245	Data on sex differences in one-year outcomes of out-of-hospital cardiac arrest patients without ST-segment elevation. <i>Data in Brief</i> , 2020, 33, 106521.	1.0	0
246	Mechanical circulatory support for shock: A little bit better is just not enough!. <i>Netherlands Heart Journal</i> , 2020, 28, 177-178.	0.8	0
247	Implementation of CT Coronary Angiography as an Alternative to Invasive Coronary Angiography in the Diagnostic Work-Up of Non-Coronary Cardiac Surgery, Cardiomyopathy, Heart Failure and Ventricular Arrhythmias. <i>Journal of Clinical Medicine</i> , 2021, 10, 2374.	2.4	0
248	MGuard Embolic Protection Stent â€“ The Importance of Thrombus Management in ST-elevation Myocardial Infarction Primary Percutaneous Coronary Intervention. <i>Interventional Cardiology Review</i> , 2014, 9, 168.	1.6	0
249	Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. , 2015, , 2281-2296.		0
250	The Impact of a Chronic Total Coronary Occlusion on Outcomes of Patients With an Implantable Cardioverter Defibrillator: Insights From the EXPLORE Trial. <i>Journal of Invasive Cardiology</i> , 2020, 32, E60-E62.	0.4	0
251	The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement. <i>Journal of Invasive Cardiology</i> , 2021, 33, E823-E832.	0.4	0
252	Cost Analysis From a Randomized Comparison of Immediate Versus Delayed Angiography After Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2022, 11, e022238.	3.7	0